This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

18 Apr 2012

Johnson & Johnson Fined $1.1B for Concealing Risperdal Risks

Johnson & Johnson has been ordered to pay $1.1 billion for failing to make clear the risks associated with its anti-psychotic drug Risperdal.

A judge in Arkansas, US, has fined pharmaceutical giant Johnson & Johnson and a subsidiary more than $1.1 billion for failing to fully disclose risks associated with the anti-psychotic drug Risperdal.


The move comes after a jury found the companies had downplayed and concealed the drug's side-effects in a letter sent to doctors in 2003.


In the letter, Johnson & Johnson stated that the medicine was safer than its rivals - a claim described by the jury as "false or deceptive".


Johnson & Johnson and Janssen Pharmaceuticals must now pay $5,000 for each of the 240,000 Risperdal prescriptions that were paid for by the state health coverage programme over a three-year period.


Related News